<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945334</url>
  </required_header>
  <id_info>
    <org_study_id>18709</org_study_id>
    <nct_id>NCT00945334</nct_id>
  </id_info>
  <brief_title>Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome</brief_title>
  <acronym>C-IBS</acronym>
  <official_title>Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Pimentel, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators aim to compare the efficacy of neomycin to a combination of
      rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test.
      This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in
      Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Constipation in Each Arm at Week 1 After Completion of Therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Visual analog scale (VAS) score for constipation:
Severity was rated using a VAS from 0 to 100 units (with 0 = no symptom and 100 = severe symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Methane From Baseline</measure>
    <time_frame>Baseline (Day 0) and Final Visit (Day 44)</time_frame>
    <description>Methane output was reported as methane in parts per million (ppm) on breath test:
Subjects fast for 12 h prior to a breath sample. Breath samples were collected via a Quintron dual bag collecting system and analyzed using a BreathTracker SC. Output was reported as methane in parts per million (ppm) after correction for alveolar sample quality using breath CO2 concentration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neomycin</intervention_name>
    <description>500 mg po bid for 14 days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Mycifradin</other_name>
    <other_name>Neo-Tab</other_name>
    <other_name>Neo-Fradin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo for 14 days tid</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>550 mg po tid</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Xifaxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rome III positive IBS subjects (18-75 years of age)

          -  Meet criteria for constipation predominant IBS symptoms including ≤ 3 complete
             spontaneous bowel movements per week with hard or lumpy stools.

          -  Presence of detectable methane on single breath sample (≥ 3ppm).

          -  If subjects are ≥ 50 years old, a colonoscopy had to have been completed within the
             past 5 years.

        Exclusion Criteria:

          -  Subjects with history of intestinal surgery (except appendectomy or cholecystectomy)

          -  Recent antibiotic use (within the last 30 days)

          -  Subjects with known pelvic floor dysfunction

          -  Pregnancy

          -  Creatinine level &gt; 1.4

          -  Poorly controlled/uncontrolled significant medical condition that would interfere with
             study procedures

          -  Subjects with hearing loss and/or tinnitus

          -  History of bowel obstruction

          -  History of celiac disease

          -  History of inflammatory bowel disease

          -  Cirrhosis

          -  Diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Pimentel, MD, FRCP(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Health Sciences University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006 Oct 17;145(8):557-63.</citation>
    <PMID>17043337</PMID>
  </reference>
  <reference>
    <citation>Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006 Aug;51(8):1297-301. Epub 2006 Jul 11.</citation>
    <PMID>16832617</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <results_first_submitted>February 25, 2015</results_first_submitted>
  <results_first_submitted_qc>July 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2015</results_first_posted>
  <last_update_submitted>July 17, 2015</last_update_submitted>
  <last_update_submitted_qc>July 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Mark Pimentel, MD</investigator_full_name>
    <investigator_title>Director, GI Motility Program</investigator_title>
  </responsible_party>
  <keyword>Constipation predominant Irritable Bowel Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Neomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Placebo: placebo for 14 days tid</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Rifaximin: 550 mg po tid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Placebo: placebo for 14 days tid</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Rifaximin: 550 mg po tid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="14.3"/>
                    <measurement group_id="B2" value="45.5" spread="16.9"/>
                    <measurement group_id="B3" value="42.8" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of Constipation in Each Arm at Week 1 After Completion of Therapy</title>
        <description>Visual analog scale (VAS) score for constipation:
Severity was rated using a VAS from 0 to 100 units (with 0 = no symptom and 100 = severe symptoms).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Placebo: placebo for 14 days tid</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Rifaximin: 550 mg po tid</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Constipation in Each Arm at Week 1 After Completion of Therapy</title>
          <description>Visual analog scale (VAS) score for constipation:
Severity was rated using a VAS from 0 to 100 units (with 0 = no symptom and 100 = severe symptoms).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" spread="24.1"/>
                    <measurement group_id="O2" value="28.6" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Methane From Baseline</title>
        <description>Methane output was reported as methane in parts per million (ppm) on breath test:
Subjects fast for 12 h prior to a breath sample. Breath samples were collected via a Quintron dual bag collecting system and analyzed using a BreathTracker SC. Output was reported as methane in parts per million (ppm) after correction for alveolar sample quality using breath CO2 concentration.</description>
        <time_frame>Baseline (Day 0) and Final Visit (Day 44)</time_frame>
        <population>Change in breath test methane gas levels: baseline breath test minus final breath test measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Placebo: placebo for 14 days tid</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Rifaximin: 550 mg po tid</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Methane From Baseline</title>
          <description>Methane output was reported as methane in parts per million (ppm) on breath test:
Subjects fast for 12 h prior to a breath sample. Breath samples were collected via a Quintron dual bag collecting system and analyzed using a BreathTracker SC. Output was reported as methane in parts per million (ppm) after correction for alveolar sample quality using breath CO2 concentration.</description>
          <population>Change in breath test methane gas levels: baseline breath test minus final breath test measurement.</population>
          <units>parts per million</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="9.739557195"/>
                    <measurement group_id="O2" value="15" spread="24.81324182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Immediately</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Placebo: placebo for 14 days tid</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
Neomycin: 500 mg po bid for 14 days
Rifaximin: 550 mg po tid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unwell</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Pimentel</name_or_title>
      <organization>Cedars-Sinai Medical Center</organization>
      <phone>3104233792</phone>
      <email>chuak@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

